Evidence map›Paper›PMID 40585426›Full record

ArticleNeurology. Genetics2025

A Retrospective Cohort Study of the GLA c.937G > T, p.Asp313Tyr Variant With No Evidence of an Association With Fabry Disease.

Tobias Boettcher, Christian Beetz, Daniel Schulze, Deepa Saravanakumar, Emir Zonic, Sabine Schroeder, Anett Kaune, Sebastian Oppermann, Omid Paknia, Jorge Pinto Basto and 1 more

Abstract read
In one paragraph

Article in Neurology. Genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tobias BoettcherCENTOGENE GmbH, Rostock, Germany.ORCID https://orcid.org/0009-0007-3264-0589
Christian BeetzCENTOGENE GmbH, Rostock, Germany.ORCID https://orcid.org/0000-0001-7061-2895
Daniel SchulzeInstitute of Biometry and Clinical Epidemiology, Charité - University Medicine Berlin, Germany; and.ORCID https://orcid.org/0000-0001-9415-2555
Deepa SaravanakumarCENTOGENE GmbH, Rostock, Germany.ORCID https://orcid.org/0009-0002-6520-9932
Emir ZonicCENTOGENE GmbH, Rostock, Germany.ORCID https://orcid.org/0009-0000-9904-3104
Sabine SchroederCENTOGENE GmbH, Rostock, Germany.ORCID https://orcid.org/0000-0001-6515-6944
Anett KauneCENTOGENE GmbH, Rostock, Germany.ORCID https://orcid.org/0009-0009-2308-1732
Sebastian OppermannCENTOGENE GmbH, Rostock, Germany.
Omid PakniaCENTOGENE GmbH, Rostock, Germany.
Jorge Pinto BastoCENTOGENE GmbH, Rostock, Germany.ORCID https://orcid.org/0000-0002-5146-613X
Peter BauerCENTOGENE GmbH, Rostock, Germany.ORCID https://orcid.org/0000-0001-9414-4555

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Fabry disease (FD) is a multisystemic disorder caused by pathogenic variants in the α-galactosidase ( Methods: By leveraging Centogene's Biodatabank, we reassessed our classification and analyzed all samples (n = 38,242) molecularly tested for FD from Germany between 2015 and 2020 for GLA genotypes, clinical presentations, and biochemical phenotypes. Results: The allele frequency of Discussion:

Identifiers

PMID40585426
PMCPMC12202016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.